Eli Lilly (LLY) confirms its to acquire Ventyx Biosciences (VYTX) for USD 14/shr

Eli Lilly's acquisition of Ventyx Biosciences at USD 14 per share suggests a strategic move to enhance its portfolio in the pharmaceutical sector.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

MARKET UPDATE: Defence stocks close lower as Trump calls for ban on buybacks and dividends until production and maintenance improves, but rally after hours as Trump says he wants 2027 defence budget boosted to USD 1.5tln from USD 1tln

Newsquawk US Market Wrap: Stocks sold as Trump takes aim at housing and defence sectors

Eli Lilly (LLY) confirms its to acquire Ventyx Biosciences (VYTX) for USD 14/shr

US President Trump says our military budget for the year 2027 should not be USD 1tln, but rather USD 1.5tln

Costco Wholesale Corporation (COST) reports December net sales of USD 29.86bln

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This deal could be seen as accretive, potentially positioning Lilly to leverage Ventyx's innovations, which may impact investor sentiment positively given the premium valuation relative to market expectations. Watch for market reactions in biotech and pharmaceutical equities, as this could indicate further consolidation trends within the industry.

Related headlines

The whole workspace, free to try.

Try it free